{
	"results": [{
			"date": "March 18, 2016",
      "code": "M19",
      "title": "Nonpharmacologic therapy and nonopioid pharmacologic therapy",
			"URL": "https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm",
			"section": "13-4",
			"priority": "high",
			"recommendation": "Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain. Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient. If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate"
		},
		{
			"date": "March 18, 2016",
			"code": "M19",
      "title": "Discuss With Patients Known Risks and Realistic Benefits of Opioid Therapy",
			"URL": "https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm",
			"section": "15-7",
			"priority": "high",
			"recommendation": "Before starting and periodically during opioid therapy, clinicians should discuss with patients known risks and realistic benefits of opioid therapy and patient and clinician responsibilities for managing therapy (recommendation"
		},
		{
			"date": "March 18, 2016",
			"code": "M19",
      "title": "Prescribe Immediate-release Opioids instead of Extended-release",
			"URL": "https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm",
			"section": "16-5",
			"priority": "high",
			"recommendation": "When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/longacting (ER/LA) opioids"
		},
		{
			"date": "March 18, 2016",
			"code": "M19",
      "title": "Prescribe Lowest Effective Dosage of Opioids",
			"URL": "https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm",
			"section": "17-6",
			"priority": "high",
			"recommendation": "When opioids are started, clinicians should prescribe the lowest effective dosage. Clinicians should use caution when prescribing opioids at any dosage, should carefully reassess evidence of individual benefits and risks when considering increasing dosage to ≥50 morphine milligram equivalents (MME)/day, and should avoid increasing dosage to ≥90 MME/day or carefully justify a decision to titrate dosage to ≥90 MME/day"
		},
		{
			"date": "March 18, 2016",
			"code": "M19",
      "title": "Evaluate Risk Factors for Opioid-Related Harms",
			"URL": "https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm",
			"section": "20-5",
			"priority": "high",
			"recommendation": "Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms. Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present"
		},
		{
			"date": "March 18, 2016",
			"code": "V70",
      "title": "Ask Patients About Their Drug and Alcohol Use",
			"URL": "https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm",
			"section": "21-7",
			"priority": "high",
			"recommendation": "Clinicians should ask patients about their drug and alcohol use. Single screening questions can be used"
		},
		{
			"date": "March 18, 2016",
			"code": "M19",
      "title": "Evaluate Risk Factors for Opioid-Related Harms",
			"URL": "https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm",
			"section": "22-6",
			"priority": "high",
			"recommendation": "Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms. Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present"
		},
    {
       "date": "March 18, 2016",
       "code": "F11",
       "title": "Medication-assisted Treatment in Combination with Behavioral Therapies",
        "URL": "https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm",
        "section": "25-2",
        "priority": "high",
        "recommendation": "Clinicians should offer or arrange evidence-based treatment (usually medication-assisted treatment with buprenorphine or methadone in combination with behavioral therapies) for patients with opioid use disorder"
        },
		{
			"date": "March 18, 2016",
			"code": "F11",
      "title": "Urine Drug Testing With Opioid Therapy",
			"URL": "https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm",
			"section": "23-10",
			"priority": "moderate",
			"recommendation": "When prescribing opioids for chronic pain, clinicians should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs"
		},

		{
			"date": "March 18, 2016",
			"code": "M19",
      "title": "Avoid Prescribing Opioid Pain Medication When Possible",
			"URL": "https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm",
			"section": "24-5",
			"priority": "moderate",
			"recommendation": "Clinicians should avoid prescribing opioid pain medication and benzodiazepines concurrently whenever possible"
		},
    {
     "date": "May 4, 2017",
     "code": "M19",
     "title": "Weight Loss and General Exercise Programs",
      "URL": "https://effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-knee-update-executive-170505.pdf",
      "section": "1-12",
      "priority": "moderate",
      "recommendation": "Weight loss and general exercise programs show medium- and longterm benefits"
      },

		{
			"date": "April 10, 2019",
			"code": "M19",
      "title": "Tracking Journal for Pain and Function",
			"URL": "https://pccds-ln.org/sites/default/files/2019-04/ LearningNetwork_OpioidActionPlan.pdf",
			"section": "16-3",
			"priority": "low",
			"recommendation": "Tracking journal for pain and function. Track functional status and pain quality, duration, intensity, location, etc. over time, setting, and circumstances to optimize therapies and management"
		},

		{
			"date": "April 10, 2019",
			"code": "F11",
      "title": "Addressing New Symptoms",
			"URL": "https://pccds-ln.org/sites/default/files/2019-04/ LearningNetwork_OpioidActionPlan.pdf",
			"section": "16-7",
			"priority": "moderate",
			"recommendation": "Provide patients with guidance on addressing new symptoms outside of clinical encounters; upload results to provider’s EHR system"
		},
		{
			"date": "April 10, 2019",
			"code": "V70",
      "title": "Asynchronous Communication Channels",
			"URL": "https://pccds-ln.org/sites/default/files/2019-04/ LearningNetwork_OpioidActionPlan.pdf",
			"section": "17-1",
			"priority": "high",
			"recommendation": "Provide asynchronous communication channels between patients, caregivers, and care teams to address concerns and share information outside of office visits; leverage rich education/ communication approaches, e.g., audio/video, interactive systems to personalize responses, etc."
		},

		{
			"date": "May 4, 2017",
			"code": "M19",
      "title": "Agility Training",
			"URL": "https://effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-knee-update-executive-170505.pdf",
			"section": "1-11",
			"priority": "low",
			"recommendation": "Agility training shows short- and long-term benefits"
		},

		{
			"date": "May 4, 2017",
			"code": "M19",
      "title": "Intra-articular Platelet-rich Plasma",
			"URL": "https://effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-knee-update-executive-170505.pdf",
			"section": "1-14",
			"priority": "low",
			"recommendation": "Intra-articular platelet-rich plasma, balneotherapy, and whole body vibration show medium-term benefits"
		}

	]

}